{
  "id": 13149233,
  "title": "New data on RevMed’s Rasonque leave potential opening for other treatments",
  "url": "https://urgent.news/2026/10/09/new-data-on-revmeds-rasonque-leave-potential-opening-for-other",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-09T15:17:24.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/new-data-on-revmeds-rasonque-leave-potential-opening-for-other-treatments/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Patients with the most common KRAS mutation in pancreatic cancer appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque, sending the company’s shares {$RVMD} down more than 6% ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}